|
Sign In to gain access to subscriptions and/or personal tools.
|
Alternative Models for Carcinogenicity Testing: Weight of Evidence Evaluations Across Models
Samuel M. Cohen
Department of Pathology and Microbiology and the Eppley Institute for Research on Cancer, University of Nebraska Medical Center, Omaha, Nebraska 68198-3135
Twenty-one chemicals were evaluated by standardized protocols in 6 mouse models that have been sugggested as alternatives to the 2-year mouse bioassay. Included were genotoxic and nongenotoxic chemicals, carcinogens and noncarcinogens, immunosuppressive and estrogenic agents, peroxisome proliferators, and chemicals producing cancer in rodents by other mechanisms. Mice were sacrificed at the end of 6 to 12 months, depending on the model. Standardized histopathology, biostatistical analyses, and criteria for overall evaluation of the results were employed. The TgAC transgenic (dermal and oral administration), the Tg-rasH2 transgenic, the heterozygous p53 gene knockout, the homozygous XPA and homozygous XPA—heterozygous p53 gene knockout, and the neonatal mouse models were evaluated. The chemicals were also evaluated in the in vitro SHE assay. Comparison of the results between the various in vivo models suggest that they might have usefulness as screening bioassays for hazard identification for potential human carcinogens. They have the benefits of being quicker, less expensive, and involve fewer animals than the traditional 2-year mouse bioassay. They do not appear to be overly sensitive. However, they do not definitively distinguish between genotoxic and nongenotoxic carcinogens, and they do not have 100% specifi city for identifying human carcinogens. Like the 2-year bioassay, the results from these models need to be evaluated in conjunction with other information on a chemical in an overall weight-of-evidence, integrated analytical approach to assess risk for human exposures.
Key Words: Chronic mouse bioassay • chronic rat bioassay • genotoxicity • risk assessment • transgenic mouse models.
References
- Boorman GA, Maronpot RR, Eustis SL (1994). Rodent carcinogenicity bioassay: Past, present and future. Toxicol Pathol 22: 105—111.[Abstract/Free Full Text]
- Box GEP (1979). Robustness in the strategy of scientifi cmodel building. In: Robustness in Statistics, Launer RL, Wilkinson GN (eds). Academic Press, New York, pp 201—235.
- Carmichael PL, Mills JJ, Campbell M., Basu M., Caldwell J. (2001). Mechanisms of hormonal carcinogenesis in the p53+/-hemizygous knockout mouse: Studies with diethylstilbestrol. Toxicol Pathol 29 (Suppl): xx—xx.
- Cohen SM (1998). Cell proliferation and carcinogenesis. Drug Metab Rev 309: 339—357.
- Cohen SM (1999). Infection, cell proliferation, and malignancy. In: Microbes and Malignancy: Infection as a Cause of Cancer, Parsonnet J, Horning S (eds). New York: Oxford University Press, pp 89—106.
- FlammangTJ,VonTungelnLS,KadlubarFF,FuPP( 1997). Neonatal mouse assay for tumorigenicity: Alternative to the chronic rodent bioassay. Regul Toxicol Pharmacol 26: 230—240.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Foran JA (1997). Principles for the Selection of Doses in Chronic Rodent Bioassays. ILSI Press, Washington, DC.
- Gulezian D., Jacobson-Kram D., McCullough CB, Olson H., Recio L., Robinson D., Storer R., Tennant R., Ward JM, Neumann DA (2000). Use of transgenic animals for carcinogenicity testing: Considerations and implications for risk assessment. Toxicol Pathol 28: 482—499.[Abstract/Free Full Text]
- International Agency for Research on Cancer (1999). Consensus report. In: Species Differences in Thyroid, Kidney and Urinary Bladder Carcinogenesis, Capen CC, Dybing E, Rice JM, Wilbourn JD (eds). IARC Scientifi c Publications, Lyon, France, 147, pp 1—14.
- International Conference on Harmonisation (1995). Technical requirements for registration of pharmaceuticals for human use. Fed Registrar 60:11278— 11286.
- Isaka H., Yoshii H., Otsuji A., Koike M., Nagai Y., Koura M., Sugiyasu K., Kanabayashi T. (1979). Tumors of Sprague-Dawley rats induced by long-term feeding of phenacetin. Gann 70: 29—36.[Web of Science][Medline]
[Order article via Infotrieve]
- Ito N., Imaida K., Asamoto M., Shirai T. (2000). Early detection of carcinogenic substances and modifi ers in rats. Mutat Res 462: 209—217.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Johansson SL (1981). Carcinogenicity of analgesics: Long-term treatment of Sprague-Dawley rats with phenacetin, phenazone, caffeine and paracetamol (acetamidophen). Int J Cancer 27: 521—529.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- JohanssonSL, AngervallL., BengtssonU., WahlqvistL. (1974). Uroepithelial tumors of the renal pelvis associated with abuse of phenacetin-containing analgesics. Cancer 33: 743—753.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Johansson SL, Wahlqvist L. (1977). Tumours of the urinary bladder and ureter associated with abuse of phenacetin-containing analgesics. Acta Pathol Microbiol Scand Sect A 85: 768—774.
- MaronpotRR, BoormanGA (1996). Thecontributionofthemouseinhazard identifi cation studies. Toxicol Pathol 24: 726—731.[Abstract/Free Full Text]
- Nakanishi K., Kurata Y., Oshima M., Fukushima S., Ito N. (1982). Carcinogenicity of phenacetin: Long-term feeding study in B6C3F1. Int J Cancer 29:439—444.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Purchase IFH, Botham PA, Bruner LH, Flint OP, Frazier JM, Stokes WS (1998). Workshop overview: Scientifi c and regulatory challenges for the reduction, refinement, and replacement of animals in toxicity testing. Toxicol Sci 43: 86—101.[Abstract/Free Full Text]
- Rall DP (2000). Laboratory animal tests and human cancer. Drug Metab Rev 32: 119—128.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Rao GN, Huff J. ( 1990). Refinementoflong-termtoxicity and carcinogenesis studies. Fundam Appl Toxicol 15: 33—43.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Swenberg JA (1995). Bioassay design and MTD setting: old methods and new approaches. Regul Toxicol Pharmacol 21: 44— 51.
- Tennant RW, French JE, Spalding JW (1995). Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ Health Perspect 103: 942—950.[Web of Science][Medline]
[Order article via Infotrieve]
- Tennant RW, Stasiewicz S., Mennear J., French JE, Spalding JW (1999). Genetically altered mouse models for identifying carcinogens. In: The Use of Short- and Medium-Term Tests for Carcinogens and Data on Genetic Effects in Carcinogenic Hazard Evaluation, McGregor DB, Rice JM, Venitt S (eds). IARC Scientifi c Publications, Lyon, France, pp 123— 150.
- van Kreul CF, van Steeg H. (1998). Transgenic mouse models for the identifi cation of human carcinogens: A European perspective. Toxicol Pathol 26: 757—758.[Free Full Text]
Toxicologic Pathology, Vol. 29, No. 1 suppl,
183-190 (2001)
DOI: 10.1080/019262301753178609
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
S. M. Cohen
Risk Assessment in the Genomic Era
Toxicol Pathol,
January 1, 2004;
32(1_suppl):
3 - 8.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. R. Payne and C. J. Kemp
p27 Kip1 (Cdkn1b)-Deficient Mice Are Susceptible to Chemical Carcinogenesis and May Be a Useful Model for Carcinogen Screening
Toxicol Pathol,
June 1, 2003;
31(4):
355 - 363.
[Abstract]
[PDF]
|
|
|
|
|
